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BLOOD HISTAMINE L E V E L S AS A POSSIBLE CLINICO-
PHARMACOLOGICAL CRITERION IN CERTAIN BLOOD 
DISEASES 
A. Belcheva, R. Mishkova* 
Department of Pharmacology and ^Department of Nephrology, Hemodyalysis and 
Haematology, Medical University of Varna, Varna 
The possible significance of blood histamine levels for diagnosing and treatment 
evaluation in patients with blood disorders such as malignant lymphomas - Hodgkin's 
disease (HD) and non-Hodgkin's lymphomas (NHL), and Schonlein-Henoch purpura 
(SHP) was studied. Histamine was established spectrofluorimetrically in the active phase 
of the disease as well as during remission after treatment. Blood levels of histamine were 
significantly decreased about 2,5-fold in patients with HD in the active phase as 
compared to healthy controls (0,030 ± 0,002 µg/ml versus 0,073 ± 0,002 µg/ml) and by 
31,5 % in patients with active SHP (0,050 ± 0,004 pig/ml versus 0,073 ± 0,002 µg/ml). 
After treatment and during remission the histamine levels recovered to normal. Such a 
correlation between blood levels of histamine, on the one hand, and process activity and 
treatment efficiency, on the other, was not observed for NHL. These results indicated that 
blood levels of histamine could serve as an additional criterion for the process activity 
evaluation and for the therapeutic effectiveness in patients with HD or SHP but not NHL. 
Furthermore, blood histamine levels might be considered as a possible clinico-
pharmacological criterion for the evaluation of new drugs anticipated for the treatment 
of HD or SHP. 
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Certain blood disorders such as 
malignant lymphomas - Hodgkin's 
disease (HD) and non-Hodgkin's 
lymphomas ( N H L ) as well as 
Schonlein-Henoch purpura (SHP) are 
usually associated with major 
immunological alterations (1,5,7). 
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Knowing that histamine can act as a 
modulator of various immune 
functions (2,8), we have been 
interested in the possible changes of 
blood histamine levels in patients 
with malignant lymphomas and SHP 
in the active phase of the disease and 
during remission due to treatment. 
The aim of the present study was to 
compare the levels of histamine in 
blood of patients with H D , N H L , and 
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SHP in the active phase and after 
treatment in order to assess the 
possible significance of blood 
histamine levels as an additional 
criterion for the diagnosis of H D , 
N H L , and SHP and for the evaluation 
of treatment. 
MATERIAL AND METHODS 
Blood samples from 97 age and 
sex mixed patients with malignant 
lymphomas - H D and N H L , or S H P 
were tested. Fifty-three of them 
presented with H D . Eleven of the 
patients were registered as N H L . The 
other 33 patients were with diagnosis 
of SHP. Blood samples were taken 
during the active phase of the disease 
before the start of treatment and 
during remission due to therapy. 
Blood samples from 45 clinically 
healthy persons served as control. 
Blood histamine levels were assayed 
spectrofluorimetrically. A l l values 
are presented as means ± S .E .M. 
Differences were assessed with 
Student's r-test. 
RESULTS AND DISCUSSION 
The mean blood concentration 
of histamine in controls was 0,073 ± 
0,002 Mg/tnl. In patients with H D 
blood histamine concentrations were 
0,030 ± 0,002 Mg/ml in the active 
phase of the disease. This is 
significantly lower (p < 0,001) by 
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Fig. 1. Blood histamine levels in patients with 
HD and SHP in the active phase of the disease 
and after treatment. Values are means ± 
S.E.M. ***p<0,001 versus controls 
2,5-fold compared to control. After 
treatment blood histamine 
concentrations became 0,077 ± 0,006 
Mg/ml thus approaching control values 
(Fig. 1). Blood histamine levels never 
reached control value in patients 
without any improvement after 
treatment. The mean concentration of 
histamine in blood of patients with 
active S H P was 0,050 ± 0,004 Mg/ml, 
which was significantly lower (p < 
0,001) by 31,5 % compared to 
control. After a course of heparin 
treatment histamine levels (0,087 ± 
0,008 Mg/ml) became slightly higher 
but not significantly different from 
the normal, healthy group (Fig. 1). In 
patients with N H L blood histamine 
levels were 0,068 ± 0,014 Mg/ml 
during the active phase and 0,050 ± 
0,007 Mg/ml during remission. There 
were no significant differences 
compared to control. 
The results from the present 
study reveal that blood levels of 
histamine are decreased below normal 
in patients with H D or S H P during the 
Blood histamine levels. 
active phase of the disease and revert 
to normal after treatment. These 
findings suggest that the assay of 
blood histamine might be helpful for 
monitoring disease activity or for 
prediction of treatment failure in 
patients with H D or SHP but not in 
patients with N H L . The observed 
changes in blood histamine 
concentration in patients with active 
H D or S H P might be related to the 
immunological alterations typical of 
these diseases. There is evidence that 
certain immunological factors such as 
interleukin-2 receptor serum levels 
could serve as prognostic indicators 
in patients with H D (3). Histamine 
itself plays an immune modulatory 
role by both augmenting or 
suppressing the immune response 
depending on the type of receptors or 
the cells present in a given 
circumstance (6). The observation 
that in patients with N H L the activity 
of the process was not associated with 
changes in blood histamine 
concentrations could be due to the 
histological and immunological 
diversity of the different types of 
N H L (4). 
The elevation of blood 
histamine levels close to the normal 
range as a result of adequate drug 
therapy might be useful as a possible 
clinico-pharmacological criterion for 
the evaluation of new drugs 
anticipated for the treatment of H D or 
SHP. 
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Нива на хистамина в кръвта като възможен клинико-
фармакологичен критерий при някои кръвни заболявания 
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Резюме: Проучено е значението на нивото на хистамина в кръвта за диагнозата и за 
преценка на ефективността от лечението при пациенти с малигнени лимфоми -
болестта на Ходжкин (БХ) и не-Ходжкинови лимфоми (НХЛ), и с пурпурата на 
Шьонлайн-Хенох (ПШХ). Хистаминът в кръвта е определян спектрофлуори-
метрично в активна фаза на заболяванията, както и в ремисия, настъпила след 
лечение. Установено е, че нивата на хистамина в кръвта са значимо по-ниски в 
активна фаза в сравнение с тези при здрави контроли - около 2,5 пъти при пациенти 
с БХ (0,030 ± 0,002 ji/ml спрямо 0,073 ± 0,002 ц/ml) и с 31,5 % - при пациенти с 
ПШХ (0,050 ± 0,004 in/ml спрямо 0,073 ± 0,002 ц/ml). След лечение и при ремисия 
съдържанието на хистамин се възстановява до нормални стойности. При НХЛ не се 
наблюдава подобна корелация между нивата на хистамина и активността на 
процеса, от една страна, както и ефективността на лечението, от друга. Резултатите 
показват, че нивото на хистамина в кръвта може да бъде използвано като 
допълнителен критерий за преценка на активността на процеса и на ефективността 
от лечението при пациенти с БХ и ПШХ, но не и при тези с НХЛ. Наред с това 
нивото на хистамина може да се обсъжда като възможен клинико-фармакологичен 
критерий при оценката на нови лекарствени средства, предлагани за лечение на БХ 
или ПШХ. 
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